

Ref: FOI/GS/ID 6537

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

01 April 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic drugs.

You asked:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab - Humira*
- b. Adalimumab Biosimilar*
- c. Apremilast*
- d. Brodalumab*
- e. Certolizumab*
- f. Dimethyl fumarate*
- g. Etanercept - Enbrel*
- h. Etanercept Biosimilar*
- i. Guselkumab*
- j. Infliximab - Remicade*
- k. Infliximab Biosimilar*
- l. Ixekizumab*
- m. Risankizumab*
- n. Secukinumab*
- o. Tildrakizumab*
- p. Ustekinumab*

Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab – Humira*
- b. Adalimumab Biosimilar*
- c. Golimumab*
- d. Infliximab – Remicade*

e. *Infliximab Biosimilar*

f. *Tofacitinib*

g. *Ustekinumab*

h. *Vedolizumab*

Q3. *If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:*

a. *Adalimumab – Humira*

b. *Adalimumab Biosimilar*

c. *Golimumab*

d. *Infliximab – Remicade*

e. *Infliximab Biosimilar*

f. *Tofacitinib*

g. *Ustekinumab*

h. *Vedolizumab*

Trust response:

Q1: The Trust is not a dermatology centre and therefore 0 to all.

Q2/Q3: The following table holds all information for both questions. Information is from Dec 2020 to Feb 2021

Drug	Drug/indication	No of patients
Amgevita	AmgevitaCrohn's disease (disorder)	1
Humira	HumiraCrohn's disease (disorder)	19
	HumiraUlcerative colitis (disorder)	3
Imraldi	ImraldiCrohn's disease (disorder)	145
	ImraldiUlcerative colitis (disorder)	47
Golimumab	GolimumabUlcerative colitis (disorder)	2
vedolizumab	vedolizumabCrohn's disease (disorder)	44
	vedolizumabUlcerative colitis (disorder)	67
ustekinumab	ustekinumabCrohn's disease (disorder)	41
	ustekinumabUlcerative colitis (disorder)	1
Tofacitinib	TofacitinibUlcerative colitis (disorder)	10
Remsima	RemsimaCrohn's disease (disorder)	104
	RemsimaUlcerative colitis (disorder)	48